By: Sarah Somers and Wayne Turner
Executive Summary
In public comments, NHeLP expresses support for Oregon’s decision to abandon its waiver of EPSDT. However, NHeLP strongly opposes Oregon’s proposal to exclude outpatient prescription drugs approved under the FDA’s accelerated approval pathway. Denying Medicaid enrollees access to effective break-through therapies would harm people with serious or life-threatening medical conditions. NHeLP also expresses concern about implementation of the EPSDT waiver withdrawal, and opposes the continued use of the prioritized list for children and adults.
